”Evaluation of the Capitainer-B Microfluidic Device as a New Hematocrit Independent Alternative for Dried Blood Spot Collection”
Newsroom
- Capitainer raises further SEK31 million to meet anticipated demand for qDBS dried blood spot sampling system as COVID-19 vaccine programs are rolled out
- Capitainer awarded ISO 13485:2016 as interest grows in qDBS testing for COVID-19 and other challenging applications
- Capitainer inks European and Asia Pacific distribution deal with Speciality Diagnostix for qDBS dried blood spot sampling system
- Swedish medtech start-up Capitainer hires VWR veteran Tom Sölch as COO amid mounting interest in novel qDBS dried blood spot sampling system for COVID-19 testing and other key applications
- TV4 news in Stockholm: 10% of Stockholm residents infected with Covid-19 based on homesampling study performed by KTH Royal Institute of Technology.
- A research study where one thousand randomely citizens of Stockholm, in Sweden, are doing home sampling using Capitainer for Covid-19 immunity – links to TV-spots and news
- Swedish Medtech start-up Capitainer raises SEK15 million to commercialise Capitainer qDBS dried blood spot sampling system
